June 25, 2012 04:08 ET

BRIC Nations to Outgrow Traditional Markets in Biologics, According to New Market Research

ROCKVILLE, MD--(Marketwire - Jun 25, 2012) - has announced the addition of the new report "Biological Strategies in the Emerging Markets - BRIC Countries Will Underpin Future Pharma Growth" to their collection of Biopharmaceuticals market reports. For more information, visit:

Biologics industry growth in the BRIC countries (Brazil, Russia, India and China) is expected to outpace traditional markets, according to a new report by business intelligence providers GBI Research.

The report states that, until recently, these emerging markets did not figure in the plans of the major pharmaceutical companies, but due to financial and political developments they are now seen as important countries in the pharmaceutical industry.

In terms of growth, it is anticipated that the BRIC countries will outstrip traditional markets like Europe and the US, albeit from a lower revenue base, in the years to come.

GBI Research reports these burgeoning economies are projected to account for over a quarter of the global biological market revenues by 2015.

The biologic sector is increasingly important to the pharma industry due to stagnation in R&D productivity and concerns over the so-called "patent cliff," with an established first generation of biologic therapies representing 24 of the top selling pharmaceutical products worldwide.

While the patent cliff has largely affected small-molecule synthetic drugs which have been the staple of pharmaceutical prosperity for decades, biologic treatments are emerging as a greater standard of care and are more difficult to replicate and manufacture.

These therapies are biological rather than chemical developments that promise greater effectiveness due to their capacity to target the underlying cause of disease and form personalized medicines.

Biological Strategies in the Emerging Markets - BRIC Countries Will Underpin Future Pharma Growth

This report discusses the growing importance of biologics and emerging markets. The key classes of biologic medicines are described, along with their therapeutic applications and importance.

In addition, significant pipeline developments in advanced clinical trials are identified. Selected companies that are already present in the biologic field are also profiled in this report.

Furthermore, the BRIC markets are described in detail. This covers their importance as pharmaceutical markets, including relevant background information such as pricing and government policies towards foreign companies, and provides a general country analysis for each.

Trends of importance to pharmaceutical market planners are also discussed, as well as strategies that are relevant for foreign companies seeking to gain a foothold in these markets.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research's team of industry experts.

For more information, visit:

About is the leading provider of global market intelligence products and services. With research reports from more than 720 top consulting and advisory firms, offers instant online access to the world's most extensive database of expert insights on global industries, companies, products, and trends. Moreover,'s Research Specialists have in-depth knowledge of the publishers and the various types of reports in their respective industries and are ready to provide research assistance. For more information, call Veronica Franco at 240-747-3016 or visit

Contact Information

  • Contact:
    Veronica Franco
    Email Contact